Codexis Inc (CDXS)
3.61
-0.16
(-4.24%)
USD |
NASDAQ |
May 17, 16:00
3.61
0.00 (0.00%)
After-Hours: 20:00
Codexis Accounts Receivable (Quarterly): 6.24M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 6.24M |
December 31, 2023 | 10.04M |
September 30, 2023 | 11.63M |
June 30, 2023 | 8.806M |
March 31, 2023 | 9.934M |
December 31, 2022 | 31.90M |
September 30, 2022 | 16.53M |
June 30, 2022 | 29.20M |
March 31, 2022 | 25.20M |
December 31, 2021 | 24.95M |
September 30, 2021 | 25.08M |
June 30, 2021 | 19.49M |
March 31, 2021 | 11.37M |
December 31, 2020 | 13.89M |
September 30, 2020 | 10.71M |
June 30, 2020 | 14.04M |
March 31, 2020 | 8.384M |
December 31, 2019 | 9.063M |
September 30, 2019 | 12.33M |
June 30, 2019 | 11.81M |
March 31, 2019 | 12.60M |
December 31, 2018 | 11.55M |
September 30, 2018 | 9.308M |
June 30, 2018 | 9.91M |
March 31, 2018 | 8.974M |
Date | Value |
---|---|
December 31, 2017 | 11.45M |
September 30, 2017 | 7.906M |
June 30, 2017 | 7.802M |
March 31, 2017 | 5.381M |
December 31, 2016 | 5.924M |
September 30, 2016 | 11.96M |
June 30, 2016 | 3.34M |
March 31, 2016 | 4.352M |
December 31, 2015 | 7.329M |
September 30, 2015 | 13.61M |
June 30, 2015 | 2.794M |
March 31, 2015 | 3.215M |
December 31, 2014 | 3.87M |
September 30, 2014 | 3.088M |
June 30, 2014 | 2.944M |
March 31, 2014 | 4.907M |
December 31, 2013 | 5.413M |
September 30, 2013 | 2.688M |
June 30, 2013 | 1.591M |
March 31, 2013 | 7.412M |
December 31, 2012 | 7.545M |
September 30, 2012 | 16.53M |
June 30, 2012 | 8.124M |
March 31, 2012 | 18.55M |
December 31, 2011 | 18.92M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
6.24M
Minimum
Mar 2024
31.90M
Maximum
Dec 2022
15.53M
Average
12.07M
Median
Accounts Receivable (Quarterly) Benchmarks
Avidity Biosciences Inc | 1.575M |
Taysha Gene Therapies Inc | -- |
Janux Therapeutics Inc | 0.519M |
Tango Therapeutics Inc | -- |
2seventy bio Inc | 11.98M |